Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Caribou Biosciences, Inc.NASDAQ: CRBU

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $1.2M fell 59.1% year over year, ahead of the -113.1% change in trailing-twelve-month other income / expenses. Sequentially, it fell 15.5% from the prior quarter.

Context

  • Other income / expenses amounted to 111.8% of revenue in FY2025, down 63.3 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -59.1% holds above the trailing-twelve-month pace of -113.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.2M-15.5% QoQ
Last fiscal yearDec 2025
-$12.48M-171.3% YoY
LTMMar 2026
-$2.06M-113.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.1%——
1 year-171.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(12.48M) USD
Year-over-year change
-171.3%

Other Income / Expenses vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -113.1% is the 9th highest of 11, against a peer median of -49.5%.
  • Other income / expenses amounts to 18.4% of revenue for CRBU, versus a peer median of 38.9%.
CRBU Competitors
Other Income / Expenses for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M USD-3.2%——
HUMAHumacyte, Inc.LTM Mar 2026$16.3M USD-51.1%-2.8%808.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$6.34M USD-47.8%-14.5%37.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$5.52M USD-41.1%+30.8%39.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M USD-67.9%-1.8%19.3%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.85M USD+44.2%——
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.85M USD-27.9%+11.8%1268.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$325K USD-86.9%—1.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$1.51M USD-146.9%+2.8%2.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$2.06M USD-113.1%—18.4%
IVAInventiva S.A.FY2025-€211.38M EUR-144.8%—4715.1%
Peer median (excluding CRBU) —-49.5%+0.5%38.9%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.